candesartan has been researched along with Infarction, Middle Cerebral Artery in 20 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Infarction, Middle Cerebral Artery: NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We have previously shown an enhanced VEGF-B expression in response to candesartan treatment after focal cerebral ischemia." | 7.88 | Silencing VEGF-B Diminishes the Neuroprotective Effect of Candesartan Treatment After Experimental Focal Cerebral Ischemia. ( Eldahshan, W; Ergul, A; Fagan, SC; Ishrat, T; Pillai, B; Soliman, S, 2018) |
| "We have shown that acute treatment with candesartan in an experimental model of stroke resulted in vascular protection and improved outcomes at 24 hours poststroke, but the mechanisms are unknown." | 7.75 | Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke. ( Abdelsaid, M; El-Remessy, AB; Elewa, HF; Ergul, A; Fagan, SC; Johnson, MH; Kozak, A; Machado, LS; Wiley, DC, 2009) |
| "Candesartan treatment normalized blood pressure and the shift toward higher blood pressures at both the upper and lower limits of cerebrovascular autoregulation in SHR." | 5.31 | Angiotensin II AT(1) blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. ( Ito, T; Nishimura, Y; Saavedra, JM, 2000) |
| " We have previously shown an enhanced VEGF-B expression in response to candesartan treatment after focal cerebral ischemia." | 3.88 | Silencing VEGF-B Diminishes the Neuroprotective Effect of Candesartan Treatment After Experimental Focal Cerebral Ischemia. ( Eldahshan, W; Ergul, A; Fagan, SC; Ishrat, T; Pillai, B; Soliman, S, 2018) |
| "We have shown that acute treatment with candesartan in an experimental model of stroke resulted in vascular protection and improved outcomes at 24 hours poststroke, but the mechanisms are unknown." | 3.75 | Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke. ( Abdelsaid, M; El-Remessy, AB; Elewa, HF; Ergul, A; Fagan, SC; Johnson, MH; Kozak, A; Machado, LS; Wiley, DC, 2009) |
| " In this study, we investigated the effect of postischemic treatment using the angiotensin II type 1 receptor blocker, candesartan, on brain damage in focal cerebral ischemia." | 3.75 | Postischemic administration of angiotensin II type 1 receptor blocker reduces cerebral infarction size in hypertensive rats. ( Kitagawa, K; Okazaki, S; Omura-Matsuoka, E; Oyama, N; Sakoda, S; Sasaki, T; Sugiyama, Y; Terasaki, Y; Yagita, Y, 2009) |
| "The aim of the study was to examine how focal cerebral ischemia affects the expression and function of vascular angiotensin II receptors." | 3.72 | Cerebral ischemia enhances vascular angiotensin AT1 receptor-mediated contraction in rats. ( Edvinsson, L; Stenman, E, 2004) |
| "Candesartan promotes angiogenesis and activates MMPs." | 1.42 | Sequential Therapy with Minocycline and Candesartan Improves Long-Term Recovery After Experimental Stroke. ( Fagan, SC; Fouda, AY; Ishrat, T; Patel, A; Pillai, B; Soliman, S, 2015) |
| "Candesartan (0·05 mg/kg) was administered just after initiation of ischaemia followed by a repeat administration at 24 h while 1, 5 isoquinolinediol (0·1 mg/kg) was given one-hour after of ischaemia." | 1.40 | A comparative study of neuroprotective effect of single and combined blockade of AT1 receptor and PARP-1 in focal cerebral ischaemia in rat. ( Hanif, K; Sharma, G; Singh, N, 2014) |
| "However, the endothelin-1 (ET-1)-induced middle cerebral artery occlusion (MCAO) model of cerebral ischaemia is thought to more closely mimic the temporal events of an embolic stroke." | 1.35 | Candesartan pretreatment is cerebroprotective in a rat model of endothelin-1-induced middle cerebral artery occlusion. ( Katovich, MJ; Mecca, AP; O'Connor, TE; Sumners, C, 2009) |
| "Transient middle cerebral artery occlusion was induced in male Wistar rats by the intraluminal filament technique for 2 h followed by recirculation." | 1.34 | Cooperative effect of angiotensin AT(1) and endothelin ET(A) receptor antagonism limits the brain damage after ischemic stroke in rat. ( Edvinsson, L; Henriksson, M; Jamali, R; Maddahi, A; Stenman, E, 2007) |
| "Therefore, 1-hour middle cerebral artery occlusion (MCAO) was followed by reperfusion." | 1.32 | The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats. ( Doerfler, A; Engelhorn, T; Forsting, M; Goerike, S; Heusch, G; Okorn, C; Schulz, R, 2004) |
| "Pretreatment with candesartan for 3 days or nicardipine for 28 days was ineffective." | 1.31 | Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist. ( Bregonzio, C; Falcón-Neri, A; Ito, T; Saavedra, JM; Terrón, JA; Yamakawa, H, 2002) |
| "Candesartan treatment normalized blood pressure and the shift toward higher blood pressures at both the upper and lower limits of cerebrovascular autoregulation in SHR." | 1.31 | Angiotensin II AT(1) blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. ( Ito, T; Nishimura, Y; Saavedra, JM, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (65.00) | 29.6817 |
| 2010's | 7 (35.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ishrat, T | 3 |
| Soliman, S | 2 |
| Eldahshan, W | 2 |
| Pillai, B | 3 |
| Ergul, A | 4 |
| Fagan, SC | 5 |
| Ahmed, HA | 1 |
| Fouda, AY | 2 |
| Sayed, MA | 1 |
| Waller, JL | 1 |
| Barakat, W | 1 |
| Safwet, N | 1 |
| El-Maraghy, NN | 1 |
| Zakaria, MN | 1 |
| Panahpour, H | 1 |
| Nekooeian, AA | 1 |
| Dehghani, GA | 1 |
| Patel, A | 1 |
| Kozak, A | 2 |
| El-Remessy, AB | 1 |
| Johnson, MH | 2 |
| Machado, LS | 1 |
| Elewa, HF | 2 |
| Abdelsaid, M | 1 |
| Wiley, DC | 1 |
| Omura-Matsuoka, E | 1 |
| Yagita, Y | 1 |
| Sasaki, T | 1 |
| Terasaki, Y | 1 |
| Oyama, N | 1 |
| Sugiyama, Y | 1 |
| Okazaki, S | 1 |
| Sakoda, S | 1 |
| Kitagawa, K | 1 |
| Mecca, AP | 1 |
| O'Connor, TE | 1 |
| Katovich, MJ | 1 |
| Sumners, C | 1 |
| Awad, AS | 1 |
| Singh, N | 2 |
| Sharma, G | 1 |
| Hanif, K | 1 |
| Ito, T | 2 |
| Yamakawa, H | 1 |
| Bregonzio, C | 1 |
| Terrón, JA | 1 |
| Falcón-Neri, A | 1 |
| Saavedra, JM | 2 |
| Stenman, E | 2 |
| Edvinsson, L | 2 |
| Engelhorn, T | 2 |
| Goerike, S | 1 |
| Doerfler, A | 2 |
| Okorn, C | 1 |
| Forsting, M | 1 |
| Heusch, G | 2 |
| Schulz, R | 2 |
| Lu, Q | 1 |
| Zhu, YZ | 1 |
| Wong, PT | 1 |
| Hamai, M | 1 |
| Iwai, M | 1 |
| Ide, A | 1 |
| Tomochika, H | 1 |
| Tomono, Y | 1 |
| Mogi, M | 1 |
| Horiuchi, M | 1 |
| Brdon, J | 1 |
| Kaiser, S | 1 |
| Hagemann, F | 1 |
| Zhao, Y | 1 |
| Culman, J | 1 |
| Gohlke, P | 1 |
| Jamali, R | 1 |
| Henriksson, M | 1 |
| Maddahi, A | 1 |
| Nishimura, Y | 1 |
1 trial available for candesartan and Infarction, Middle Cerebral Artery
| Article | Year |
|---|---|
RAS modulation prevents progressive cognitive impairment after experimental stroke: a randomized, blinded preclinical trial.
Topics: Amyloid beta-Peptides; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood P | 2018 |
19 other studies available for candesartan and Infarction, Middle Cerebral Artery
| Article | Year |
|---|---|
Silencing VEGF-B Diminishes the Neuroprotective Effect of Candesartan Treatment After Experimental Focal Cerebral Ischemia.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Brain Ischemia; Disease Models, Animal; Infarction, Mid | 2018 |
Candesartan and glycyrrhizin ameliorate ischemic brain damage through downregulation of the TLR signaling cascade.
Topics: Adaptor Proteins, Vesicular Transport; Animals; Behavior, Animal; Benzimidazoles; Biphenyl Compounds | 2014 |
Candesartan attenuates ischemic brain edema and protects the blood-brain barrier integrity from ischemia/reperfusion injury in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood-Brain Ba | 2014 |
Sequential Therapy with Minocycline and Candesartan Improves Long-Term Recovery After Experimental Stroke.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Brain Infarcti | 2015 |
Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Behavior, Animal; Benzimidazoles; Biphenyl Compoun | 2009 |
Postischemic administration of angiotensin II type 1 receptor blocker reduces cerebral infarction size in hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2009 |
Candesartan pretreatment is cerebroprotective in a rat model of endothelin-1-induced middle cerebral artery occlusion.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Brain Ischemia | 2009 |
Effect of combined treatment with curcumin and candesartan on ischemic brain damage in mice.
Topics: Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; Blood Flow Velocity; Brain; Cerebrovascul | 2011 |
A comparative study of neuroprotective effect of single and combined blockade of AT1 receptor and PARP-1 in focal cerebral ischaemia in rat.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Brain; Brain E | 2014 |
Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2002 |
Cerebral ischemia enhances vascular angiotensin AT1 receptor-mediated contraction in rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds | 2004 |
The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2004 |
Neuroprotective effects of candesartan against cerebral ischemia in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Body Weight; B | 2005 |
Comparison of inhibitory action of candesartan and enalapril on brain ischemia through inhibition of oxidative stress.
Topics: Analysis of Variance; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pr | 2006 |
Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Brain; Cerebra | 2006 |
Comparison between early and delayed systemic treatment with candesartan of rats after ischaemic stroke.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2007 |
Blood pressure lowering after experimental cerebral ischemia provides neurovascular protection.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Are | 2007 |
Cooperative effect of angiotensin AT(1) and endothelin ET(A) receptor antagonism limits the brain damage after ischemic stroke in rat.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Brain Ischemia | 2007 |
Angiotensin II AT(1) blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; | 2000 |